The FDA enforcement report carries a series of Class II recalls from a US compounding firm covering semaglutide–cyanocobalamin and tirzepatide–cyanocobalamin injections supplied in pre-filled syringes. The stated reason is lack of assurance of sterility, linked to the formulation and the processing equipment. The recall status is listed as ongoing.
A Class II recall means use of the product may cause temporary or reversible harm, or that serious harm is unlikely. It is a manufacturing-quality action, not a finding about semaglutide or tirzepatide as medicines.
These products are US compounded preparations. Whether any have reached Indian patients is unknown, but patients who buy GLP-1 agonists online or abroad are increasingly common, and compounded vitamin-B12 combinations are a marker of that supply chain.
- Ask patients on a GLP-1 or GIP/GLP-1 agonist where they obtain it, especially if the product is a combination with vitamin B12.
- Treat injection-site redness, swelling or fever in a patient using a compounded product as possible contamination.
- This recall concerns sterility of compounded syringes, not the safety of licensed semaglutide or tirzepatide.
- Advise patients to use licensed, pharmacy-dispensed products where they are available.
Why it matters
Demand for these drugs has created a grey supply, and sterility failures are its predictable hazard.
Don't overread it
A sterility recall of compounded product says nothing about the efficacy or safety of the licensed medicines.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for diabetes & endocrinology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free